JP2009512673A5 - - Google Patents

Download PDF

Info

Publication number
JP2009512673A5
JP2009512673A5 JP2008536136A JP2008536136A JP2009512673A5 JP 2009512673 A5 JP2009512673 A5 JP 2009512673A5 JP 2008536136 A JP2008536136 A JP 2008536136A JP 2008536136 A JP2008536136 A JP 2008536136A JP 2009512673 A5 JP2009512673 A5 JP 2009512673A5
Authority
JP
Japan
Prior art keywords
sina
seq
sirna
modification
ribonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512673A (ja
JP5677721B2 (ja
Filing date
Publication date
Priority claimed from GBGB0521351.7A external-priority patent/GB0521351D0/en
Application filed filed Critical
Publication of JP2009512673A publication Critical patent/JP2009512673A/ja
Publication of JP2009512673A5 publication Critical patent/JP2009512673A5/ja
Application granted granted Critical
Publication of JP5677721B2 publication Critical patent/JP5677721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008536136A 2005-10-20 2006-10-20 Ｔｒｐｖ発現レベルの制御 Active JP5677721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0521351.7A GB0521351D0 (en) 2005-10-20 2005-10-20 Modulation of TRPV expression levels
GB0521351.7 2005-10-20
PCT/GB2006/050342 WO2007045930A2 (en) 2005-10-20 2006-10-20 Modulation of trpv expression levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013007528A Division JP2013074902A (ja) 2005-10-20 2013-01-18 Ｔｒｐｖ発現レベルの制御

Publications (3)

Publication Number Publication Date
JP2009512673A JP2009512673A (ja) 2009-03-26
JP2009512673A5 true JP2009512673A5 (https=) 2012-08-09
JP5677721B2 JP5677721B2 (ja) 2015-02-25

Family

ID=35458356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008536136A Active JP5677721B2 (ja) 2005-10-20 2006-10-20 Ｔｒｐｖ発現レベルの制御
JP2013007528A Pending JP2013074902A (ja) 2005-10-20 2013-01-18 Ｔｒｐｖ発現レベルの制御

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013007528A Pending JP2013074902A (ja) 2005-10-20 2013-01-18 Ｔｒｐｖ発現レベルの制御

Country Status (15)

Country Link
US (1) US8354385B2 (https=)
EP (1) EP1937281B1 (https=)
JP (2) JP5677721B2 (https=)
AT (1) ATE493994T1 (https=)
AU (1) AU2006305657B2 (https=)
CA (1) CA2626181C (https=)
CY (1) CY1111384T1 (https=)
DE (1) DE602006019458D1 (https=)
DK (1) DK1937281T3 (https=)
ES (1) ES2358538T3 (https=)
GB (1) GB0521351D0 (https=)
PL (1) PL1937281T3 (https=)
PT (1) PT1937281E (https=)
SI (1) SI1937281T1 (https=)
WO (1) WO2007045930A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010117178A (ru) * 2007-10-01 2011-11-10 Алькон Рисерч, Лтд. (Us) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN104471063A (zh) * 2012-06-20 2015-03-25 独立行政法人科学技术振兴机构 核酸复合物及核酸多糖复合物
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
KR101681229B1 (ko) 2013-07-24 2016-11-30 고려대학교 산학협력단 TRPV4 활성 억제제로서의 vorinostat의 용도
GB202219829D0 (en) 2022-12-29 2023-02-15 Ivy Farm Tech Limited Genetically manipulated cells
WO2025215354A1 (en) 2024-04-08 2025-10-16 Ivy Farm Technologies Limited Method of culturing an animal cell

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL16768C (https=) 1924-10-02
US4343794A (en) * 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) * 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) * 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) * 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) * 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6365576B1 (en) * 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040115815A1 (en) 2002-07-24 2004-06-17 Immusol, Inc. Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker
WO2004009794A2 (en) 2002-07-24 2004-01-29 Immusol, Inc. NOVEL siRNA LIBRARIES AND THEIR PRODUCTION AND USE
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
NZ540779A (en) * 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (de) * 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) * 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) * 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004099372A2 (en) * 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US20040224405A1 (en) * 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp RNAI THERAPEUTIC FOR THE TREATMENT OF EYE DISEASES WITH VASCULAR REPRODUCTION
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
AU2005222902B2 (en) * 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
HRP20171010T8 (hr) * 2004-08-23 2017-11-03 Sylentis S.A.U. Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
KR20080018858A (ko) 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해

Similar Documents

Publication Publication Date Title
JP7406793B2 (ja) ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
JP6453275B2 (ja) 非対称性干渉ｒｎａの組成物およびその使用
DK3222724T3 (en) ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
US10590423B2 (en) Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
US10947541B2 (en) Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
JP2020039361A (ja) 筋強直性ジストロフィープロテインキナーゼ（ｄｍｐｋ）の発現を調節するための化合物及び方法
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
JP2014097072A5 (https=)
CN104379152B (zh) 寡核苷酸螯合物方法
TW201336514A (zh) ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
JP2009512673A5 (https=)
CN120752341A (zh) 靶向sod1的寡核苷酸
WO2007084359A2 (en) Compositions and methods for the treatment of influenza infection
JP2009513112A (ja) アラビノース修飾ヌクレオチドを含む低分子干渉リボ核酸二重鎖
WO2025002247A1 (zh) 靶向人血管生成素样蛋白3的核酸及其用途
JP6830441B2 (ja) 治療上のｕｎａオリゴマーおよびその使用
WO2014009609A1 (en) Combination therapy iii
RU2788030C2 (ru) Структуры мирнк с высокой активностью и сниженным воздействием вне мишени
CN101351231A (zh) 包含阿拉伯糖修饰的核苷酸的小干扰核糖核酸双螺旋
AU2018200311A1 (en) Further novel forms of interfering rna molecules